Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/12/2003EP1289561A2 Ligand conjugates and methods for preparing same
03/12/2003EP1289559A1 Combinations of enzyme inhibitor-containing preparations and the use thereof
03/12/2003EP1289556A2 Phytoestrogenic isoflavone compositions
03/12/2003EP1289553A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
03/12/2003EP1289552A2 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
03/12/2003EP1289543A2 Formulations and methods for treating hypercoagulable states
03/12/2003EP1289536A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders
03/12/2003EP1289534A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
03/12/2003EP1289531A2 Kits and methods for optimizing the efficacy of chondroprotective compositions
03/12/2003EP1289525A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/12/2003EP1289514A1 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
03/12/2003EP1289510A2 Compositions, kits, and methods for promoting defined health benefits
03/12/2003EP1289508A2 Method for the prevention of apoptosis
03/12/2003EP1289507A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
03/12/2003EP1289446A2 Cardiac disease treatment and device
03/12/2003EP1097127B1 Diacylhydrazine derivatives as integrin inhibitors
03/12/2003EP1083891B1 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
03/12/2003EP1044203B1 3'-epimeric k-252a derivatives
03/12/2003EP1019426B1 Novel a1 adenosine receptor agonists and antagonists
03/12/2003EP0983287B1 Novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions
03/12/2003EP0831881B1 Cetp for increasing hdl cholesterol level
03/12/2003EP0763039B1 42-rapamycin hydroxyester, process for its preparation and pharmaceutical compositions containing it
03/12/2003EP0758243B1 BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa
03/12/2003EP0729459B1 Phenyl-alkyl imidazoles as h3-receptor antagonists
03/12/2003CN1402733A Angiogenic proteins and uses thereof
03/12/2003CN1402732A Nb heterocyclic 8-modified adenosine derivs.
03/12/2003CN1402730A Thiazolo (4,5-D) pyrimidine compounds
03/12/2003CN1402729A Polycycloalkylpurines as adenosine receptor antagonists
03/12/2003CN1402724A Thiazolidinedione derivs. as antidiabetic agents
03/12/2003CN1402721A Benzoimidazole derivs. useful as antiproliferative agents
03/12/2003CN1402716A Substd. oxazoles and thiazoles derivs. as HPPAR alpha activators
03/12/2003CN1402712A Novel heterocyclic compounds and salts thereof and medicinal use of same
03/12/2003CN1402711A 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor
03/12/2003CN1402704A Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methane-sulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
03/12/2003CN1402703A Tri-substd. phenyl derivs. and analogues
03/12/2003CN1402637A Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
03/12/2003CN1401384A Pueraria root and Hovenia dulcis fruit preparation
03/12/2003CN1401374A Semifluid motherwort extract and producing process thereof
03/12/2003CN1401357A External applied medical ointment for treating piles
03/12/2003CN1401356A Chinese medicine patch film and method for producing same
03/12/2003CN1401347A Brain and heart recovery pill
03/12/2003CN1401341A Medicinal powder 'Pianfusan' for treating hemiplegia
03/12/2003CN1401339A Oral liquid capable of reducing blood fat and improving symptom of myocardial ischemia and infarction
03/12/2003CN1401326A Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof
03/12/2003CN1401322A Concentrated clear solution contg. biocefalin as brain metabolism improving medicine for intravenous injection after diluting it
03/12/2003CN1401317A Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase
03/12/2003CN1102848C Chemical medicine composition for treating hypertension
03/12/2003CN1102847C Medicine or nutrient contg. daidzein material
03/12/2003CA2422067A1 Aminoheterocycles (factor xa inhibitors 14)
03/11/2003US6531622 Crytalline form of (s)-2 ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy)phenyl]propanoic acid
03/11/2003US6531612 Nitrile derivatives that inhibit cathepsin K
03/11/2003US6531600 Treatment and compounds
03/11/2003US6531580 Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
03/11/2003US6531511 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
03/11/2003US6531498 Antiallergens, etc
03/11/2003US6531492 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/11/2003US6531486 Reacting quinapril or acid addition salt thereof with alkaline magnesium compound in presence of solvent to form quinapril magnesium
03/11/2003US6531479 Anti-cancer compounds
03/11/2003US6531478 For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders
03/11/2003US6531474 Inhibitors of caspases
03/11/2003US6531471 Morpholinone and morpholine derivatives and uses thereof
03/11/2003US6531469 Substituted 1-(4-piperidyl)-3-(aryl) isothioureas their preparation and their therapeutic application
03/11/2003US6531458 Stable formulation for oral administration
03/11/2003US6531450 Use treating neuropathological situations caused by the aging of the nervous system; MP52, MP121 are growth or/and differentiation factors of the TGF-beta (transforming growth factor) superfamily
03/11/2003US6531449 Hexahydropyrazolo[4,3,-c]pyridine metabolites
03/11/2003CA2264254C Phosphinic acid amides as matrix metalloprotease inhibitors
03/11/2003CA2038416C Ascorbic acid derivatives
03/10/2003CA2401358A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/07/2003WO2002020481A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
03/07/2003WO2002020472A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/07/2003CA2421835A1 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridines
03/07/2003CA2421781A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/06/2003WO2003019198A2 Methods relating to treatment of atherosclerosis
03/06/2003WO2003019196A2 Diagnosis and treatment of atherosclerosis
03/06/2003WO2003019146A2 High throughput screening assays using fatty acid synthetic enzymes
03/06/2003WO2003018803A1 Established fat cell precursors, method of preparing the same and method of using the same
03/06/2003WO2003018758A2 Reagents and methods for smooth muscle therapies
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018754A2 Neural regeneration peptide and methods for their use in treatment of brain damage
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018639A1 Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander
03/06/2003WO2003018595A2 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003WO2003018591A1 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions
03/06/2003WO2003018589A1 Novel 4-aminofuropyrimidines and the use thereof
03/06/2003WO2003018581A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018574A1 Rapamycin dialdehydes
03/06/2003WO2003018573A1 Rapamycin 29-enols
03/06/2003WO2003018564A1 Vascular wall-selective acat inhibitor
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018553A1 Oral antidiabetic agents
03/06/2003WO2003018538A1 Novel diarylalkene derivatives and novel diarylalkane derivatives
03/06/2003WO2003018516A2 Glucagon-like peptide-1 analogs
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018069A1 Preparation and diabetic use of gibberellins
03/06/2003WO2003018061A1 Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
03/06/2003WO2003018059A2 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003WO2003018058A1 Myocardial cell apoptosis inhibitors
1 ... 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 ... 1595